What is he best known for?
The fields of study he is best known for:
His main research concerns Immunology, Mannan-binding lectin, Molecular biology, Lectin and Antibody.
His Immunology study integrates concerns from other disciplines, such as Respiratory disease, Mannan, Cystic fibrosis and Transmembrane protein.
His Mannan-binding lectin research incorporates elements of Serine protease, Leukemia and Immunopathology.
Claus Koch has included themes like Haplotype, Allele, Genotype and Blot in his Molecular biology study.
His work on MBL deficiency as part of general Lectin research is frequently linked to Cyprinus, thereby connecting diverse disciplines of science.
His Antibody research integrates issues from Radioimmunoassay, Chromatography and Yolk.
His most cited work include:
- Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment (400 citations)
- Pathogenesis of cystic fibrosis (370 citations)
- Mannose-binding lectin deficiency--revisited (361 citations)
What are the main themes of his work throughout his whole career to date?
Claus Koch mainly investigates Molecular biology, Antibody, Immunology, Monoclonal antibody and Antigen.
As part of one scientific family, he deals mainly with the area of Molecular biology, narrowing it down to issues related to the Biochemistry, and often Complement system and Lectin pathway.
Claus Koch combines topics linked to Immune system with his work on Antibody.
His Immunology study combines topics from a wide range of disciplines, such as Internal medicine, Cystic fibrosis and Mannan.
His study focuses on the intersection of Monoclonal antibody and fields such as Immunoassay with connections in the field of Chromatography.
His work is dedicated to discovering how Antigen, Microbiology are connected with Virology and other disciplines.
He most often published in these fields:
- Molecular biology (34.04%)
- Antibody (29.79%)
- Immunology (27.66%)
What were the highlights of his more recent work (between 2007-2018)?
- Complement system (12.77%)
- Lectin pathway (7.45%)
- Molecular biology (34.04%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Complement system, Lectin pathway, Molecular biology, Biochemistry and Immunology.
The Complement system study which covers Lectin that intersects with Ciona intestinalis.
Claus Koch interconnects Complement and Ficolin in the investigation of issues within Lectin pathway.
His studies in Molecular biology integrate themes in fields like In vitro, Mutant, Immunity and Enzyme.
His work on Immunology is being expanded to include thematically relevant topics such as Internal medicine.
His research integrates issues of Cystic fibrosis and Antigen in his study of Antibody.
Between 2007 and 2018, his most popular works were:
- A Novel Mannose-binding Lectin/Ficolin-associated Protein Is Highly Expressed in Heart and Skeletal Muscle Tissues and Inhibits Complement Activation (130 citations)
- Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. (105 citations)
- The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients (86 citations)
In his most recent research, the most cited papers focused on:
Claus Koch spends much of his time researching Complement system, Molecular biology, Antibody, Mannan-binding lectin and Biochemistry.
His work on Lectin pathway as part of his general Complement system study is frequently connected to Quartz crystal microbalance, Silicone and Silicone rubber, thereby bridging the divide between different branches of science.
Claus Koch does research in Molecular biology, focusing on Ficolin specifically.
Antibody is a subfield of Immunology that Claus Koch tackles.
His Immunology research incorporates themes from Mannan and Cystic fibrosis.
His research on Biochemistry focuses in particular on Lectin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
